Supplementary Materials for

Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques

Kevin R. Bewley, Karen Gooch, Kelly M. Thomas, Stephanie Longet, Nathan Wiblin, Laura Hunter, Kin Chan, Phillip Brown, Rebecca A. Russell, Catherine Ho, Gillian Slack, Holly E. Humphries, Leonie Alden, Lauren Allen, Marilyn Aram, Natalie Baker, Emily Brunt, Rebecca Cobb, Susan Fotheringham, Debbie Harris, Chelsea Kennard, Stephanie Leung, Kathryn Ryan, Howard Tolley, Nadina Wand, Andrew White, Laura Sibley, Charlotte Sarfas, Geoff Pearson, Emma Rayner, Xiaochao Xue, Teresa Lambe, Sue Charlton, Sarah Gilbert, Quentin J. Sattentau, Fergus Gleeson, Yper Hall, Simon Funnell, Sally Sharpe, Francisco J. Salguero, Andrew Gorringe*, Miles Carroll*

*Corresponding author. Email: andrew.gorringe@phe.gov.uk (A.G.); miles.carroll@phe.gov.uk (M.C.)

Published 10 September 2021, Sci. Adv. 7, eabg7996 (2021)
DOI: 10.1126/sciadv.abg7996

This PDF file includes:

Figs. S1 to S4
a. SDS-PAGE. Lane 1, molecular weight markers; lane 2, medium only; lane 3, live virus; lane 4, inactivated virus.
b. Western blot probed with MERS convalescent S3 serum. Lane 1, molecular weight markers; lane 2, live virus; lane 3 inactivated virus.
c. Western blot probed with anti-RBD (lanes 2-4) or anti-nucleocapsid polyclonal antiserum (lanes 5-7). Lane 1, molecular weight markers; lane 2, medium only; lane 3, live virus; lane 4, inactivated virus; lane 5, medium only; lane 6, live virus; lane 7 inactivated virus.
Supplementary figure 2

(A) Weight - Ferret

(B) Temperature - Ferret

(C) Weight – rhesus macaque

(D) Temperature – rhesus macaque
SARS-CoV-2-specific IFN-γ spot forming unit (SFU) frequency measured by ELISPOT in PBMCs and splenocytes following vaccination with formaldehyde-inactivated virus (FIV) or control/no vaccine and subsequent infection with SARS-CoV2. A) SARS-CoV-2-specific SFU in splenocytes and PBMCs isolated from ferrets 6-8 days following SARS-CoV2 infection. B) Spike-specific SFU in PBMCs isolated from macaques. FIV vaccination administered at timepoint Day -14, SARS-CoV2 infection at Day 0. C) Spike-specific SFU measured in splenocytes 6-8 days following SARS-CoV-2 infection. Black = no vaccine, Red = FIV. Each square represents one animal and bar at median. Mann-Whitney U-test significance values shown (p ≤ 0.05). D) Quantification of CD4+ and CD8+ T cells expressing PD-1 prior to (day -14), 14 days after FIV vaccination (day 0) and at days 3 and 6-8 days (day 7) following SARS-CoV2 infection in NHPs. E) Quantification of NHP CD4+ T-regulatory cells determined by expression of CD25 and CD127 by whole blood immunophenotyping flow cytometry assay. Box plots show the group median +/- the inter-quartile range, with minimum and maximum values connected by whiskers. Asterisks denote significant differences determined by Wilcoxon signed rank test for paired comparisons, (*) p ≤ 0.05.
Representative example of pulmonary abnormalities identified on images constructed from CT scans five days after SARS-CoV-2 challenge collected from macaques that did not receive a vaccination A – E and macaques that received FIV vaccine F, G, H. Green arrows indicate areas of ground glass opacification, yellow arrows indicate areas of consolidation. Images from macaques that did not have abnormal features are not shown. Plots show the scores attributed for possession of characteristic features associate with COVID (pattern score) [H] and distribution of the abnormalities through the lung (zone score) [I] in non-vaccinated and FIV-vaccinated macaques showing non-significant trends for reduction in severity in the FIV group (pattern score \( p = 0.0519 \), zone score \( p = 0.3052 \)) Mann-Whitney U-tests; Box plots show the experimental group median with +/- IQR indicated by box whiskers, symbols show scores measured in individual animals.